Prelude Therapeutics (PRLD) Invested Capital (2019 - 2026)

Prelude Therapeutics has disclosed Invested Capital across 8 years of filings, most recently posting $60.2 million for Q1 2026.

• Invested Capital for Q1 2026 came in at $60.2 million, down 41.67% year-over-year; the trailing twelve-month figure through Mar 2026 was $60.2 million (down 41.67% YoY), and the FY2025 annual result was $68.6 million, down 47.79% from the prior year.
• Invested Capital came in at $60.2 million for Q1 2026 at Prelude Therapeutics, down from $68.6 million in the prior quarter.
• In the past five years, Invested Capital ranged from a high of $262.1 million in Q2 2023 to a low of $58.5 million in Q3 2025.
• The 5-year median for Invested Capital is $182.3 million (2024), against an average of $169.1 million.
• Across the five-year window, Invested Capital gained 21.31% in 2023 and plunged 62.58% in 2025, its largest moves.
• Prelude Therapeutics' Invested Capital stood at $195.4 million in 2022, then rose by 21.31% to $237.1 million in 2023, then tumbled by 44.55% to $131.5 million in 2024, then tumbled by 47.79% to $68.6 million in 2025, then slipped by 12.32% to $60.2 million in 2026.
• The last three Invested Capital figures came in at $60.2 million (Q1 2026), $68.6 million (Q4 2025), and $58.5 million (Q3 2025), per Business Quant data.